Treatment with givinostat has received fast track designation from the United States Food and Drug Administration for ...

Children with a rare muscle wasting disease are being denied access to a groundbreaking new life-extending treatment, the Sunday Mail can reveal. Givinostat slows the progress of Duchenne muscular ...

The FDA has granted Fast Track designation to Italfarmaco S.p.A.’s givinostat for the treatment of patients with polycythemia vera (PV).

The CHMP recommends conditional marketing authorization for Duvyzat to treat Duchenne muscular dystrophy in patients aged 6 ...

Michael Rankin, 12, who is desperately waiting for access to the drug, said: “Every second they don’t get this through, one person might not be able to walk again”.